Vera Therapeutics Grants Inducement Awards to Two New Hires Under Nasdaq Rule 5635(c)(4)

On February 2, 2026, the Compensation Committee of Vera Therapeutics' board approved equity awards for two people who had just joined the company. The Brisbane, California biotech, listed on Nasdaq under the ticker VERA, announced the grants four days later, on February 6.

The package has two parts. The first is a set of non-qualified stock options to purchase 11,500 shares of Class A common stock. The second is restricted stock units covering 5,750 shares of the same class. Both were issued under the Vera Therapeutics, Inc. 2024 Inducement Plan, and both went to the two new employees. The announcement does not give their names or roles, nor how the totals divide between them.

The committee approved the awards as an inducement material to each person's employment, which is the language Nasdaq Listing Rule 5635(c)(4) requires. That rule is why the grants were disclosed in a press release at all.

The options carry an exercise price of $45.28 per share, matching Vera's closing price on February 2, the day of the grant. They vest over four years. A quarter of the underlying shares vest on the first anniversary of the applicable vesting commencement date. The remainder vest monthly over the following 36 months. Vesting depends on the employee remaining in a service relationship with the company through each date.

The RSUs follow a slightly different schedule. They also vest over four years, with 25% of the underlying shares vesting on each anniversary of February 20, 2026, again conditional on continued service. All awards are governed by the terms of the Inducement Plan and by the award agreement for each grant.

The release also restates what Vera does. It describes itself as a late clinical-stage biotechnology company working on treatments for serious immunological diseases. Its lead candidate is atacicept, a fusion protein that patients inject themselves at home once a week under the skin. It blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), two signals that prompt B cells to make autoantibodies tied to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN) and lupus nephritis. Vera says it is evaluating further diseases where reducing autoantibodies could prove meaningful.

Two other programs are named. VT-109 is a next-generation BAFF and APRIL fusion protein licensed exclusively from Stanford University. MAU868 is a monoclonal antibody designed to neutralize BK virus infection, which can have devastating consequences for kidney transplant recipients. Vera says it retains all global development and commercial rights to all three.

Nothing in the announcement points to a change in the company's pipeline or finances. It is a routine hiring disclosure. The investor contact is Joyce Allaire of LifeSci Advisors, and the media contact is Debra Charlesworth at Vera Therapeutics.